The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,901–2,000 of 2,716
Nguyen, T. T. H., Le, K., Tran, T. A. T., Nguyen, K. N., Can, T. B. N., Bui, P., Tran, D., & Vu, C. D. (2025) · Diagnostics · doi:10.3390/diagnostics15121534 · Cited by 3
“Serum 25-hydroxyvitamin D [25(OH)D] levels were determined by electrochemiluminescence immunoassay on the same analyzer.”
Performance of afternoon (16:00 h) serum cortisol for the diagnosis of Cushing’s syndrome
Dupuis, H., Merlen, E., Elices-Diez, J., Balayé, P., Cortet, C., Jannin, A., Cao, C. D., Douillard, C., SOULEZ, B., Ramdane, N., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0133 · Cited by 2
Mosquera, J. E., Rahimi, L., & Hamidi, O. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000920 · Cited by 3
Hypertension and kidney dysfunction despite long-term remission of Cushing’s syndrome
Ritzel, K., Fedtke, V., Then, C., Nowak, E., Vogel, F., Braun, L., Zopp, S., Zimmermann, P., Peters, A., Heier, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02670-w · Cited by 1
Mutlu, Ü., Rasulova, N., Hacışahinoğulları, H., Yalın, G. Y., Gül, N., Üzüm, A. K., & Selçukbiricik, Ö. S. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02668-4 · Cited by 1
“Chronic supraphysiological GC exposure can lead to metabolic syndrome, glucose intolerance, diabetes, hypertension, dyslipidemia, osteoporosis, decreased muscle strength, sarcopenia, and cardiovascular problems, as in Cushing’s syndrome [ 12].”
Pokrzywa, A., Pachucki, J., Bobrowicz, M., Koperski, Ł., & Ambroziak, U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1649633 · Cited by 2
Valizadeh, M., Seifi, Z., & Abiri, B. (2025) · Endocrine · doi:10.1007/s12020-025-04452-z · Cited by 1
Clinical efficacy and safety of fluconazole treatment in patients with Cushing’s syndrome
Liao, T.-Y., Lin, Y.-C., Huang, C., Hwu, C., & Lin, L. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251372275 · Cited by 1
“1,26 If the patient’s condition allowed, one or more of these tests were performed, and the final diagnosis was made based on a comprehensive interpretation of the combined results.”
Meunier, S. M., Voegel, C. D., Neubert, E., Harburger, L. A., Riond, B., Hofmann‐Lehmann, R., Boretti, F. S., & Sieber‐Ruckstuhl, N. S. (2025) · BMC Veterinary Research · doi:10.1186/s12917-025-05064-5 · Cited by 1
“Salivary cortisol is in equilibrium with the biologically active free cortisol in the blood and is not affected by the rate of saliva production [7].”
Should Hypercortisolism Be Part of Your Differential Diagnosis?
Ray, R., & Cruse, D. R. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2025.105562 · Cited by 2
Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease
Mondin, A., Ceccato, F., Scaroni, C. M., Denaro, L., Manara, R., Robertazzo, U. M., & Barbot, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1695342 · Cited by 2
Amani‐Beni, R., Shervedani, A. K., Darouei, B., Noroozi, M., & Heidarpour, M. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71419 · Cited by 1
Jung, C., Derbyshire, M. M., Jauhar, N., Bennett, D., Topliss, D. J., Gogna, R., Markovic, N., Burgess, J. R., & Inder, W. J. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf188 · Cited by 2
“At our centers, other second-line diagnostic tests, such as the midnight serum cortisol or the dexamethasone-suppressed corticotropin-releasing hormone stimulation (Dex-CRH) test [23], were performed infrequently.”
Gao, Y., Mu, D., Ma, Y., Li, Y., Li, M., Hu, Y., Qiu, L., Yu, S., & Cheng, X. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.017 · Cited by 3
Iatrogenic Cushing’s Syndrome and the Hidden Ingredient of Artri King
Ataallah, B., & Tameemi, M. A. (2026) · Cureus · doi:10.7759/cureus.100843 · Cited by 1
“Endogenous hypercortisolism is less common, with an estimated incidence of 2-3 cases per million per year [4].”
Deryol, H. Y., Tek, S., Akpinar, E., Erkan, B., Keskin, Ü., Tuna, M. M., Niyazoğlu, M., & Hatipoğlu, E. (2026) · HORMONES · doi:10.1007/s42000-025-00750-3 · Cited by 2
Neurocognitive changes after radiation to the pituitary region
Murphy, P., Mitchell, A. C., Edge, D., Shekhda, K. M., Baldeweg, S. E., & Kosmin, M. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag002 · Cited by 1
Garg, M., Gulfishan, S., Mazhari, B. B. Z., Alam, M. W., Sirohi, A., Mathew, S., & Varghese, A. (2026) · Biochimie · doi:10.1016/j.biochi.2026.01.015 · Cited by 3
Adrenocortical Carcinoma Presenting With Concurrent Cushing Syndrome and Primary Hyperaldosteronism
Eisa, N. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.003 · Cited by 1
Cortisol assays across the physiologic spectrum: access immunoassay compared with LC-MS/MS
Newman, A. J., Mahrokhian, S., Hanna, I., Tsai, C., Salle, S. P., Brown, J. M., Stouffer, D. G., Auchus, R. J., & Vaidya, A. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag043 · Cited by 2
Anilkumar, A. S., Thomas, S. M., & Veerabathiran, R. (2026) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2026.104870 · Cited by 1
Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience
Muradov, İ., Sahin, S., Akpinar, S., Tunc, A., Kocaman, B. B., Soltanova, L., Saricoban, C. T., Çomunoğlu, N., Tanrıöver, N., Gazioğlu, N., et al. (2026) · Clinical Endocrinology · doi:10.1111/cen.70121 · Cited by 1
“Among patients diagnosed with CS based on screening and confirmatory tests, those with ACTH levels > 20 pg/mL were classified as having ACTH‐dependent CS [15].”
Old and new pituitary biomarkers: evidence for sex-specificity
Schweizer, J. R. D. O. L., & Schilbach, K. (2026) · Pituitary · doi:10.1007/s11102-026-01650-4 · Cited by 1
“[ 17 , 19] Cortisol by LC–MS/MS (vs. immunoassay) Not sex-specific per se but reduces analytical bias that can obscure biologic differences.”
InfluentialCirculating immune profiles in ACTH-dependent Cushing's syndrome
Liu, J., Zhou, X., Zhu, H., Duan, L., Wang, L., zhao, Y., Zhang, Q., Qiu, L., Zhang, Y., Deng, K., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag060 · Cited by 1
Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions
Şahin, Ö. F., Tosunoğlu, Z., Şahin, R., et al. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006405 · Cited by 1
Management Approach of Adrenal Incidentaloma
Kabbani, M., & Berber, E. (2026) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1177/10926429261443897 · Cited by 1
Chasan, O., Terzioglu, M. B. B., Mutlu, Ü., Burak, D. D., Hacışahinoğulları, H., Gül, N., Selçukbiricik, Ö. S., Üzüm, A. K., & Yalın, G. Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1798032 · Cited by 2
Management of persistent and recurrent Cushing’s disease: Efficacy of repeat transsphenoidal surgery
Nasi‐Kordhishti, I., Gött, H., Wiggenhauser, L. M., & Honegger, J. B. (2026) · Endocrine · doi:10.1007/s12020-026-04638-z · Cited by 1
Apaydın, T., Keklikkıran, Ç., Kani, H. T., Yilmaz, Y., & Yavuz, D. G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02876-6 · Cited by 2
Honegger, J. B., Grimm, F., Gött, H., & Nasi‐Kordhishti, I. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag115 · Cited by 1
Systemic and cardiac pathology induced by a clinically relevant USP8 activating mutation
González, T., Galicia-Martín, A., Calle, D., Cussó, L., Soto‐Navarrete, M. T., Luo, X., Méndez-Peralta, L., Grego‐Bessa, J., & de la Pompa, J. L. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052695 · Cited by 1
“To assess HPA axis activation in our model, we measured the free cortisol index relative to creatinine in urine samples, a standardized screening for human and canine patients with CD (Nieman et al., 2008; Schaferet al., 2023).”
Parasiliti‐Caprino, M., Ponzetto, F., Bianco, A. D., Barba, L., Febbraro, E., Sola, C., Leoni, L., Bima, C., Mengozzi, G., Aimaretti, G., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag132 · Cited by 3
Zhang, C., Zhang, J., & Zhao, F. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119050 · Cited by 1
Antonelli, G., TRETTI, G., Aita, A., Sciacovelli, L., & Montagnana, M. (2026) · Biochimica Clinica · doi:10.23736/s0393-0564.26.00210-4 · Cited by 1
Unklare Gewichtszunahme bei einer 41-jährigen Frau
Harsch, I. A., & Hahn, E. G. (2009) · Der Internist · doi:10.1007/s00108-009-2461-4 · Cited by 1
Belaya, Z. E., Rozhinskaya, L. Y., Dragunova, N. V., Solodovnikov, A. G., Ilyin, А. V., Mel'nichenko, G. A., Dedov, I. I., & Dzeranova, L. K. (2012) · Osteoporosis and Bone Diseases · doi:10.14341/osteo201223-8 · Cited by 3
Störungen der Nebennierenfunktion
Partsch, C., & Riepe, F. G. (2014) · Springer eBooks · doi:10.1007/978-3-642-41866-2_65 · Cited by 1
Marova, E. I., Arapova, S., Kolesnikova, G. S., et al. (2013) · Problems of Endocrinology · doi:10.14341/probl201359411-17 · Cited by 1
CASO INUSUAL DE SÍNDROME DE CUSHING.
BORGES, M., Pizzolante, I., Marante, D., Pastrán, Z., Malave, S. R., Rebolledo, N., Mattout, J., Manso, A., Chaparro, M., & Iglesias, M. J. (2014) · Actualidad Contable FACES · Cited by 1
Cushing syndrome, metabolic syndrome and inflammation: a suggested way out
Esposito, K. (2013) · Reviews in Endocrinology and Metabolism · doi:10.11138/rem/2013.1.1.041 · Cited by 1
Draft of Russian Guidelines of Diagnosis and Treatment of Adrenal Cortical Cancer
Mel'nichenko, G. A., Stilidi, I. S., Горбунова, В. А., Alexeev, B. Y., Beltsevich, D. G., Райхман, А. О., Kuznetsov, N. S., Zhukov, N. V., & Bokhyan, V. Y. (2014) · Endocrine Surgery · doi:10.14341/serg201414-26 · Cited by 2
““ПРОТИВ” – пожилой возраст, отсутствие заболеваний, в генезе которых может участвовать гиперкорти цизм, развитие послеоперационной надпо чечниковой недостаточности [16].”
Cicognani, C., Vezzadini, C., Battaglia, S., Marliani, A. F., & Zoni, R. (2010) · Italian Journal of Medicine · doi:10.4081/itjm.2010.37 · Cited by 2
Dreval, A. V., Владимировна, К. И., Murzina, A. V., Nechaeva, O., Степановна, Т. Р., Borodina, E., & Anashkina, G. A. (2014) · Problems of Endocrinology · doi:10.14341/probl20146019-17 · Cited by 1
Should the Monitoring Protocols for Adrenal Incidentalomas be Changed?
Mateo-Gavira, I., Vílchez-López, F. J., Larrán-Escandón, L., Ojeda-Schuldt, M. B., Tinoco, C. L., & Aguilar‐Diosdado, M. (2014) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2013.09.030 · Cited by 1
Hagemann, K., Calderari, M. Z., Perren, A. A., Cree, I. A., Mullis, P. E., & Flück, C. E. (2011) · HORMONES · doi:10.14310/horm.2002.1324 · Cited by 1
Diagnostics of Cushing's disease in the children (a literature review)
Udalova, N. (2011) · Problems of Endocrinology · doi:10.14341/probl201157557-62 · Cited by 1
Osteoporosis asociada a glucocorticoides, una aproximación práctica. Revisión
Yurgaky, J. M., & Ana María Arredondo, G. (2010) · Revista Med · doi:10.18359/rmed.1313 · Cited by 2
Zarrinpar, A., & Yeh, M. W. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0857-5_10 · Cited by 2
“Only patients with (1) clinical features unusual for their age, (2) multiple and progressive features described above, (3) or adrenal incidentalomas compatible with adenoma, and (4) children with decreasing height percentile and increasing weight should be tested for Cushing’s syndrome [ 79 ].”
BackgroundInfluentialCushing's syndrome as a cause of secondary obesity and metabolic syndrome: a case report
Cuttica, C. M., Monte, P. D., Cardillo, T., Robotti, P. C., Foppiani, L., Marugo, A., Oppezzi, M., Quilici, P., & Arlandini, A. (2009) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1007/s12349-009-0053-4 · Cited by 1
Management of incidental pituitary tumors
Marko, N. F., & Weil, R. J. (2011) · Oncology Reviews · doi:10.1007/s12156-011-0088-x · Cited by 1
Medical management of Cushing’s syndrome
Morgan, F. H., & Laufgraben, M. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.3 · Cited by 1
Endokrinologische Laboruntersuchungen – wo liegen die Probleme?
Henzen, C., KRAENZLIN, M. E., & Meier, C. (2013) · Therapeutische Umschau · doi:10.1024/0040-5930/a000435 · Cited by 1
“3 nmol/l als robust und hochsen sitiv für einen Hyperkortisolismus und die zweimalige Bestimmung wird als Screeningtest empfohlen [22].”
BackgroundApplication de la spectrométrie de masse en exploration hormonale
Fiet, J., Giton, F., & Guechot, J. (2011) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(11)71214-x · Cited by 1
Pancreatic Neuroendocrine Tumor Presenting as a Cushing’s Syndrome Associated with Hypertension
Ivonye, C. C. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000132 · Cited by 1
“It is important to note that patients with rapid onset of Cushing’s syndrome and weight loss in the setting of an elevated ACTH levels may have an ectopic source of ACTH production usually from small cell lung cancer [3].”
BackgroundLong-Term Follow-Up of Cushing’s Disease: A Case Report
Baş, V. N., Ağladıoğlu, S. Y., Önder, A., Özışık, P., Kendırcı, H. N. P., & Semra, Ç. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.993 · Cited by 1
“The classic characteristic of this disease is the lack of suppression in low-dose dexamethasone tests but its presence in highdose dexamethasone tests (1,3,4).”
BackgroundInfluentialClinical Presentation and Initial Diagnosis
Allolio, B., & Faßnacht, M. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_4 · Cited by 1
MEN 2A con doble mutación en gen RET: carcinoma medular de tiroides secretor de ACTH
Ares, J., Díaz-Naya, L., Martín-Nieto, A., et al. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.11.004 · Cited by 1
The Diagnosis of Pediatric Cushing's Syndrome is not always simple
Zadik, Z. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.091 · Cited by 1
Takayanagi, R., Kawate, H., & Yanase, T. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.941 · Cited by 1
Владимировна, К. И., Dreval', A. V., Чеканова, А. В., & Анатольевна, А. Л. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2016-44-4-430-438 · Cited by 3
Secondary Hypertension: Differential Diagnosis and Basic Principles of Treatment
Jaćović, S., Radojević, M. Ž., & Petrović, D. (2016) · Serbian Journal of Experimental and Clinical Research · doi:10.1515/sjecr-2015-0056 · Cited by 1
Medical Management for Pituitary Adenoma Patients
Hong, G. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-56691-7_21 · Cited by 1
Endocrine Disorders and the Cardiovascular System
Ghaemmaghami, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00032-8 · Cited by 1
Ambroziak, U., Kuryłowicz, A., Kępczyńska‐Nyk, A., Kondracka, A., Gajda, S., & Sieńko, D. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13628 · Cited by 1
“Saliva is widely used as a screening test in Cushing’s syndrome (CS) diagnostics.(2) It is a useful tool in”
MethodCushing’s Syndrome and Glucocorticoid Excess
Koch, C. A. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_28 · Cited by 2
Capatina, C. A.-M., Baciu, I. F., Greere, D., Caragheorgheopol, A., & Poiană, C. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0008 · Cited by 1
“While it is clearly not recommended to screen patients with DM for hypercortisolism unless they have other symptoms or signs suggestive for the disorder [3], diabetologists should be aware of the characteristic features of hypercortisolism and assess them appropriately on a patient-basis.”
BackgroundMethodInfluentialDi, D. G., Vicennati, V., Rinaldi, E., Morselli‐Labate, A. M., Giampalma, E., Mosconi, C., Pagotto, U., & Pasquali, R. (2012) · 15th International & 14th European Congress of Endocrinology · Cited by 1
Grebennikova, T. A., Belaya, Z. E., Solodovnikov, A. G., Il'yin, A. V., Nikankina, L. V., & Mel'nichenko, G. A. (2018) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn904 · Cited by 1
Multiple myeloma concealed by adrenal Cushing syndrome: a case report and review of the literature
Wannachalee, T., Jantanapornchai, N., Suphadirekkul, K., Sirinvaravong, S., & Owattanapanich, W. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1731-y · Cited by 1
Pituitary Tumors and Craniopharyngiomas
Suh, J. H., Chao, S. T., Murphy, E. S., & Weil, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00029-0 · Cited by 3
Nebennierenüberfunktion bei Kindern und Jugendlichen
Kamrath, C., & Riepe, F. G. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57309-9_35 · Cited by 1
Demidowich, A. P., Asia, M. F., & Bertherat, J. Y. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_36 · Cited by 1
The Main Provisions of the International Recommendations on Detection of Endocrine Hypertension
Vaychulis, I. A., & Иосифович, Ш. И. (2019) · Kardiologiia · doi:10.18087/cardio.2019.10.2669 · Cited by 2
Munir, A., & Newell-Price, J. D. C. (2009) · Medicine · doi:10.1016/j.mpmed.2009.05.013 · Cited by 2
Self-citationPrognostic markers of remission of cushing's disease after transsphenoidal endoscopic adenomektomii.
Gussaova, N., Choi, W. A., Cherebillo, V. Y., Paltsev, A. A., Savello, A. V., Ryazanov, P. A., Mitrofanova, L. B., Солнцев, В. Н., & Grineva, E. N. (2018) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-12-1106-1111 · Cited by 1
Lethielleux, G., & Bertherat, J. Y. (2020) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(20)44310-7 · Cited by 3
Андреева, Н. А., Kachanov, D. Y., Ilyina, E. Y., Shcherbakov, А. P., Терещенко, Г. В., Likar, Y. N., Druy, A. E., Roshchin, V. Y., Yadgarov, M. Y., & Shamanskaya, T. V. (2020) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2020-19-4-66-81 · Cited by 1
Cushing’s syndrome and pregnancy: diagnostic, treatment and management tactics
Golounina, O. O., Pavlova, M. G., Gronskaia, S., Казначеева, Т. В., Dzeranova, L. K., Belaya, J. E., & Fadeev, V. V. (2021) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush2021210515 · Cited by 3
Japp, E., Alba, E. L., & Levine, A. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_20 · Cited by 1
Neuropsychiatric symptoms in a patient with Cushing’s syndrome
Daya, R., Seedat, F., Blomerus, E., Bulbulia, S., & Bayat, Z. (2022) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v28i0.1706 · Cited by 2
Cushing’s syndrome due to ectopic adrenocorticotropin secretion by a parotid carcinoma
Antonacio, F. F., Harada, G., VILELA, R. S., Freitas, T. C., Lima, J. V., Kowalski, L. P., Almeida, M. Q., & de Castro, G. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000426 · Cited by 1
Zada, G., Woodmansee, W. W., Kaiser, U. B., & Laws, E. R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-166-0_16 · Cited by 2
Allolio, B., Nies, C., Moll, R., Klose, K., Kann, P. H., Pfestroff, A., Waldmann, J., Bartsch, D. K., Lehnert, H., Dralle, H., et al. (2012) · Springer eBooks · doi:10.1007/978-3-642-14285-7_4 · Cited by 1
Care of the Child with a Pediatric Endocrine Disorder
Crespi, R., Pughe, L., & Dowd, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-90642-9_11 · Cited by 1
Blood Tests for the Diagnosis of Adrenal Diseases
Cha, S., & Moon, S. D. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.6.532 · Cited by 1
Adenomas hipofisarios funcionantes
Fernández-Rodríguez, E., Bernabéu, I., & Casanueva, F. F. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70380-3 · Cited by 1
Hipertensión secundaria: ¿cuándo y cómo buscarla?
Arbeláez, N. Z., Estacio, M. A., Sierra-Vargas, E. C., Díaz, J. C., & Gómez, J. S. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.20000001 · Cited by 2
Zhao, S., He, Y., Wang, H., Li, D., Gong, L., Zhang, Y., & Li, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863017 · Cited by 3
Carton, M., & Buggy, D. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00028-1 · Cited by 1
Diagnosis and Treatment of Secondary Hypertension
Song, S. H., Choi, H. S., & Bae, E. H. (2022) · Korean Journal of Medicine · doi:10.3904/kjm.2022.97.3.171 · Cited by 1
Back to Basics—When Should Cushing Syndrome Be Suspected?
Ragnarsson, Ó. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac531 · Cited by 1
Circulating FK506 binding protein 51 mRNA expression in patients with pituitary adenomas
Yang, Y., Babayan, L., Mirzakhanian, A., Sisliyan, N., Zhang, D., Hurtado, C., Zahid, A., Bergsneider, M., Kim, W. B., Wang, M. B., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2022.e12678 · Cited by 2
Wehbeh, L., Alwahab, U. A., Mikhael, A., Dobri, G. A., Yogi-Morren, D., Kennedy, L., & Hamrahian, A. H. (2023) · Endocrine · doi:10.1007/s12020-023-03327-5 · Cited by 1
Jatoi, A., & Haider-Badenhorst, Y. (2023) · Cureus · doi:10.7759/cureus.42589 · Cited by 1
“In fact, in the practice guidelines published by the Journal of Clinical Endocrinology & Metabolism [4], it is recommended that patients with a suspected diagnosis of Cushing’s syndrome or an adrenal incidentaloma and two concordant negative test results need not undergo further investigations.”
BackgroundApproach to the patient with adrenal incidentaloma. Case series
Ladygina, D. O., Zorina, A. A., Berkovskaya, M. A., Chevais, A., Beltsevich, D. G., & Fadeev, V. V. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.4.202306 · Cited by 1
“вечернего кортизола слюны должны быть использованы для подтверждения диагноза [26].”
Unilateral adrenalectomy as a treatment option in a patient with recurrent Cushing’s disease
Gosmanov, A. R., Green, M., Gerges, A. K., Ziganshina, A., & Roy, M. (2023) · Oxford Medical Case Reports · doi:10.1093/omcr/omad084 · Cited by 1
Endocrine Disorders Associated with Obesity
Park, H. K., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_42-2 · Cited by 1
Osteoporosis as the First Sign of Cushing’s Disease in a Thin 16-Year-Old Boy—A Case Report
Łupińska, A., Aszkiełowicz, S., Zieliński, G., Stawerska, R., & Lewiñski, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185967 · Cited by 2
“We considered cut-off points for diagnosing CD to be a 35% increase in ACTH concentration at 15 and/or 30 min, and at least a 20% increase in cortisol concentration at 30 and 45 min [16,17].”
MethodMetabolomics of Rare Endocrine, Genetic Disease: A Focus on the Pituitary Gland
Masood, A., Malkawi, A. K., Rahman, A. M. A., & Siaj, M. (2023) · Springer eBooks · doi:10.1007/978-981-99-5162-8_8 · Cited by 1
Secondary Hypertension: Primary Hyperaldosteronism and Mineralocorticoid Excess States
Young, W. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00014-1 · Cited by 2
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.